Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-19. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport; not approved as medicine | Listed by WADA at all times. |
| Common synonyms | GW501516, GW-501516, endurobol | Cardarine is a colloquial name. |
| Typical analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Common test matrix | Urine | Blood and dried blood spots also possible. |
| Legal classification | Varies by country | Often treated as unapproved drug or research chemical. |
This exposes the diabetic foot to thermal or mechanical trauma, and to the late detection of infection processes or tissue breakdown; effects on foot morphology (deformities): due to most of the above alterations, a significant imbalance of peripheral musculature and soft tissue occurs in the foot, which seriously alters its morphology and determines the onset of foot deformities. Most common deformities of the diabetic foot are represented by a high longitudinal arch (rigid cavus foot), hammer toes, and hallux valgus. A completely different morphologic degeneration is represented by neuropathic arthropathy, whose analysis is not part of this discussion.
Those who have used topical corticosteroids over a prolonged period of time Those who have used corticosteroids to cover a large surface area Those with broken skin barrier or extensive abrasions Those who have recently undergone stress (such as illness, trauma, surgery) Children under the age of 12 HPA axis suppression is preventable by supplementation with glucocorticosteroids. If HPA axis suppression occurs, it is often reversed shortly after discontinuation of treatment.
== Career and research == To juggle parenting and research, Masur moved to the new Medical School at Mount Sinai as an Instructor (part-time) in the Department of Physiology and Biophysics in 1968. where the chairman also provided her with a full-time research assistant. Masur continued as a research associate at Columbia University completing her post-doctoral training in cytochemistry. In collaboration with Eric Holtzman she hypothesized that organelle membrane insertion and removal from the cell surface was the basis for hormone induced alteration in cell membrane permeability. Interest in cell-matrix interaction led her to the cornea where she studied the roles of the extracellular matrix, cell-cell interactions and soluble factors in the wound healing process using a corneal stroma model. Masur's laboratory was funded for 35 years by the National Institutes of Health to explore the hormonal control of membrane transport as well as the cellular mechanisms of wound healing. Her lab determined that myofibroblasts and fibroblasts in the cornea are not "terminally differentiated".
Sources: en.wikipedia.org
=== Story === For the first year of development, the team focused mostly on the gameplay without narrative structure. Playtesters found the game fun but asked about what these test chambers were leading towards. This prompted the team to come up with a narrative for Portal. The team worked with Marc Laidlaw, the writer of the Valve's Half-Life series, to fit Portal into the Half-Life universe. This was done in part because of the project's limited art resources; instead of creating art assets for Portal, the team reused the Half-Life 2 assets. Laidlaw opposed the crossover, feeling it "made both universes smaller", and said later: "I just had to react as gracefully as I could to the fact that it was going there without me. It didn't make any sense except from a resource-restricted point of view." Valve hired Erik Wolpaw and Chet Faliszek to write Portal. Wolpaw felt that the constraints improved the game. The concept of a computer AI guiding the player through experimental facilities to test the portal gun was arrived at early in the writing process. They drafted early lines for a "polite" AI with humorous situations, such as requesting the player's character to "assume the party escort submission position", and found this style of approach to be well-suited to the game they wanted to create, leading to the creation of the GLaDOS character. GLaDOS was central to the plot.
=== Hydrodynamic model === Transport through pores – in the simplest case – is done convectively. This requires the size of the pores to be smaller than the diameter of the two separate components. Membranes that function according to this principle are used mainly in micro- and ultrafiltration. They are used to separate macromolecules from solutions, colloids from a dispersion, or remove bacteria. During this process, the retained particles or molecules form a pulpy mass (filter cake) on the membrane, and this blockage of the membrane hampers the filtration. This blockage can be reduced by the use of the cross-flow method (cross-flow filtration). Here, the liquid to be filtered flows along the front of the membrane and is separated by the pressure difference between the front and back of the membrane into retentate (the flowing concentrate) on the front and permeate (filtrate) on the back. The tangential flow on the front creates a shear stress that cracks the filter cake and reduces the fouling.
JTT (1992). Published in the same year as BLOSOM, it also performs clustering and uses an implicit model. This may help reduce the systematic error from maximum parismony (MP), but also wastes sequence information. VTML (2001), a PAM-like matrix based on the alignments in the SYSTERS database, iteratively improved using a maximum likelihood estimator starting from the 1970s Dayhoff PAM model. WAG (Wheelan And Goldman, 2001) uses a maximum likelihood estimating procedure instead of any form of MP over a "BRKALN" dataset. The substitution scores are calculated based on the likelihood of a change considering multiple tree topologies derived using neighbor-joining. The scores correspond to a substitution model which includes also amino-acid stationary frequencies and a scaling factor in the similarity scoring. There are two versions of the matrix: WAG matrix based on the assumption of the same amino-acid stationary frequencies across all the compared protein and WAG* matrix with different frequencies for each of included protein families. PMB (Probability Matrix from Blocks, 2003), a set of "true" substitution frequencies estimated from the observed frequencies of BLOSUM, taking into account the possibility of a later substitution masking a previous one. It thus creates a evolutionary model where the distances have theoretical meaning (BLOSUM does not have this feature, unlike PAM, WAG, and most other later matrices, and hence is not recommended for phylogeny by IQ-TREE). LG (2008), which uses a larger dataset (Pfam-based) than WAG.
Sources: en.wikipedia.org
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.
Laboratories use liquid chromatography-tandem mass spectrometry to detect GW501516 and its metabolites. Urine is commonly tested, and testing can occur in and out of competition.
No, cardarine is not a SARM. It is a PPARδ agonist, which acts on a different receptor. The two classes are often confused in online discussions.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.